Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care

• Published in: Acta diabetologica Vol. 59; no. 7; pp. 921 - 928
• Main Authors: Boscari, Federico, Ferretto, Sara, Cavallin, Francesco, Fadini, Gian Paolo, Avogaro, Angelo, Bruttomesso, Daniela
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.07.2022; Springer Nature B.V
• Subjects: Diabetes; Diabetes mellitus (insulin dependent); Fear; Glucose; Glucose monitoring; Hyperglycemia; Hypoglycemia; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Original; Original Article; Psychological aspects; Flash glucose monitoring-Free Style Libre 1 and 2; Type 1 diabetes; Glucose control; Time in range
• ISSN: 1432-5233; 0940-5429; 1432-5233
• DOI: 10.1007/s00592-022-01884-1

Aim Whether glucose sensor alarms improve metabolic control and are accepted by individuals with diabetes is unclear. Here, we investigated whether switching from a standard flash glucose monitoring system (FGM1) to a system equipped with hypo- and hyperglycemia alarms (FGM2) improves glycemic control and psychological outcomes in adults with type 1 diabetes (T1D). Methods Subjects with T1D and > 4% of time in hypoglycemia or > 40% of time in hyperglycemia were studied while wearing FGM1 (4 weeks) and after switching to FGM2 for 8 weeks. The primary endpoint was the change in time in range (TIR 70–180 mg/dl [3.9–10.0 mmol/L]) after 4 weeks of FGM2 use. Time below range (TBR), time above range (TAR), mean glucose, coefficient of variation (CV), sensor scans, treatment satisfaction, and hypoglycemia fear were secondary outcomes. Results We included 38 subjects aged 33.7 ± 12.6 year. During 4 weeks of FGM2 use, TIR increased from 52.8 to 57.0% ( p  = 0.001), TBR decreased from 6.2 to 3.4% ( p  < 0.0001) as did time < 54 mg/dl (from 1.4 to 0.3%, p  < 0.0001) and CV (from 39.6% to 36.1%, p  < 0.0001). These changes were confirmed after 8 weeks of FGM2 use. Treatment satisfaction improved and fear of hypoglycemia decreased. Subjects who had > 4% of time in hypoglycemia at baseline showed the greatest improvements in glucose control and treatment satisfaction. Conclusion Switching from FGM1 to FGM2 improved TIR and treatment satisfaction and reduced fear of hypoglycemia. Participants who benefited most from switching from FGM1 to FGM2 were those prone to hypoglycemia.